Senti Biosciences, Inc.
SNTI
$2.10
$0.041.94%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 21.50% | 9.59% | 5.72% | -14.80% | -4.81% |
| Gross Profit | -21.50% | -9.59% | -5.72% | 14.80% | 1.13% |
| SG&A Expenses | 28.05% | 97.98% | -10.86% | -15.61% | -26.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.25% | 29.25% | -2.25% | -15.17% | -15.44% |
| Operating Income | -24.25% | -29.25% | 2.25% | 15.17% | 13.79% |
| Income Before Tax | 37.21% | -31.51% | -16.52% | 96.74% | 21.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 37.21% | -31.51% | -16.52% | 96.74% | 21.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 37.21% | -31.51% | -16.52% | 96.74% | -93.43% |
| EBIT | -24.25% | -29.25% | 2.25% | 15.17% | 13.79% |
| EBITDA | -26.19% | -32.41% | 1.99% | 15.77% | 12.44% |
| EPS Basic | 89.04% | 76.95% | 46.81% | 67.94% | -87.94% |
| Normalized Basic EPS | 71.55% | 77.28% | 46.93% | 93.57% | 3.65% |
| EPS Diluted | 89.04% | 76.95% | 46.81% | 67.94% | -87.94% |
| Normalized Diluted EPS | 71.55% | 77.28% | 46.93% | 93.57% | 3.65% |
| Average Basic Shares Outstanding | 473.03% | 470.46% | 119.07% | 4.37% | 2.92% |
| Average Diluted Shares Outstanding | 473.03% | 470.46% | 119.07% | 4.37% | 2.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |